No Data
No Data
IDEAYA Biosciences: Buy Rating Affirmed Amid FDA Breakthrough and Promising Clinical Developments
Express News | IDEAYA Biosciences Inc: Targeting to Initiate a Ph3 Registrational Study in Neoadjuvant Um in H1 2025
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
Express News | IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for Ide275 (GSK959), a Phase 1 Werner Helicase Inhibitor
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
Ideaya Biosciences Announced A Research Collaboration With ATTMOS As Part Of Its Efforts To Build A Physics-based Computational Small Molecule Discovery Platform To Target Undruggable Oncology Targets